After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...